Anavex Life Sciences’ (AVXL) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a report issued on Tuesday morning,Benzinga reports. They currently have a $20.00 price objective on the biotechnology company’s stock.

Several other equities research analysts have also commented on AVXL. Weiss Ratings restated a “sell (d-)” rating on shares of Anavex Life Sciences in a research note on Monday, December 29th. D. Boral Capital reissued a “buy” rating and set a $24.00 price target on shares of Anavex Life Sciences in a report on Monday. Finally, Jones Trading cut Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 24th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $22.00.

Anavex Life Sciences Trading Down 9.0%

AVXL opened at $3.96 on Tuesday. The company has a market cap of $353.83 million, a price-to-earnings ratio of -8.61 and a beta of 1.21. The company’s 50 day moving average is $4.30 and its 200 day moving average is $6.97. Anavex Life Sciences has a 12-month low of $2.86 and a 12-month high of $13.99.

Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Monday, February 9th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.04. As a group, analysts predict that Anavex Life Sciences will post -0.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Anavex Life Sciences

Several institutional investors and hedge funds have recently modified their holdings of AVXL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Anavex Life Sciences by 10.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,525 shares of the biotechnology company’s stock worth $434,000 after buying an additional 4,869 shares in the last quarter. Stratos Wealth Partners LTD. bought a new stake in Anavex Life Sciences in the 2nd quarter valued at $245,000. 180 Wealth Advisors LLC increased its holdings in Anavex Life Sciences by 213.4% in the 2nd quarter. 180 Wealth Advisors LLC now owns 44,050 shares of the biotechnology company’s stock valued at $406,000 after acquiring an additional 29,995 shares during the last quarter. Atria Investments Inc lifted its stake in Anavex Life Sciences by 18.2% in the 2nd quarter. Atria Investments Inc now owns 22,110 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 3,406 shares in the last quarter. Finally, Kovack Advisors Inc. bought a new position in shares of Anavex Life Sciences during the 2nd quarter valued at about $93,000. Institutional investors own 31.55% of the company’s stock.

Key Stories Impacting Anavex Life Sciences

Here are the key news stories impacting Anavex Life Sciences this week:

• Positive Sentiment: Analysts reiterated bullish ratings and high price targets — HC Wainwright reaffirmed a Buy with a $20 target and D. Boral Capital kept a Buy with a $24 target, reflecting sizable upside vs. the current share level. Analyst Reaffirmations
• Positive Sentiment: Quarterly results beat expectations: AVXL reported EPS of ($0.06) vs. consensus ($0.10), a narrower loss and a reduced net loss vs. year-ago. Cash rose to $131.7M, implying more than three years of runway at current burn — a meaningful de‑risk on financing needs. Q1 Results & Business Update
• Positive Sentiment: Regulatory engagement in the U.S. shows constructive dialogue — Anavex reported FDA Type C meeting feedback indicating the agency’s interest and collaborative approach on potential NDA pathways, which could accelerate clarity on approval requirements. FDA Type C Feedback
• Neutral Sentiment: Company hosted an investor webcast and multiple transcripts of the Q1 call are available for details on milestones, clinical plans and cash runway. Useful for investors wanting the management take. Earnings Call Transcript
• Neutral Sentiment: Coverage pieces noting potential breakeven and progress in programs (e.g., Parkinson’s, Rett syndrome, ANAVEX 3-71) frame a multi-indication pipeline narrative but are speculative pending regulatory outcomes. Breakeven Analysis
• Neutral Sentiment: Short-interest data in the feed is effectively nil/invalid for February (reported as 0 shares / NaN), so short-squeeze dynamics are not a clear factor today. (No linked article.)
• Negative Sentiment: Regulatory risk in Europe: the EMA’s CHMP previously issued a negative opinion on blarcamesine’s marketing application and the company is pursuing re-examination. That EU uncertainty (described as leaving blarcamesine in “regulatory purgatory”) is the primary near-term negative catalyst pressuring the stock. Seeking Alpha: Negative EU Opinion

About Anavex Life Sciences

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.